Table 3.
Atazanavir pharmacokinetic comparison before versus after etonogestrel implant initiation in postpartum women living with HIV, 2012–2015 (N=74).
| Parameter | Before ENG Median (range) N=22 | After ENG Median (range) N=22 | Geometric mean of before/after initiation ratio [90% CI] | *P-value of Wilcoxon signed rank test comparison |
|---|---|---|---|---|
| AUC0–24 (μg*hr/mL) | 53.962 (8.739,157.300) | 55.254 (9.471,157.567) | 1.101 [0.840, 1.443] | 0.3669 |
| CL/F (L/hr) | 5.560 (1.907,34.331) | 5.445 (1.904,31.676) | 0.908 [0.693, 1.191] | 0.5184 |
| Tmin (hr) | 10 (0, 24) | 0 (0,24) | 0.3096 | |
| Tmax (hr) | 3 (2,4) | 2 (1,6) | 0.9077 | |
| T1/2 (hr) | 17.154 (9.076,67.577) | 18.206 (6.510,152.105) | 0.888 [0.681, 1.156] | 0.4980 |
| Vd/F (L) | 157.238 (43.345,505.124) | 185.475 (61.989,1,866.663) | 0.732 [0.550, 0.975] | 0.1054 |
| Cmin (μg/mL) | 0.929 (0.024,4.673) | 0.411 (0.024,4.539) | 2.333 [1.121, 4.855] | 0.0921 |
| Cmax (μg/mL) | 4.392 (0.638,10.402) | 4.647 (0.643,8.563) | 1.167 [0.835, 1.630] | 0.4780 |
| C0(μg/mL) | 1.078 (0.024,6.572) | 0.593 (0.024,5.129) | 2.505 [1.070, 5.864] | 0.1074 |
| C12(μg/mL) | 1.792 (0.290,5.763) | 1.463 (0.276,6.309) | 1.211 [0.871, 1.682] | 0.5184 |
| C24h (μg/mL) | 1.206 (0.116,4.673) | 1.064 (0.126, 4.539) | 1.391 [0.965, 2.003] | 0.0600 |
p-value for Wilcoxon signed rank test. Geometric means are not calculated for Tmin and Tmax, and ties (differences of zero) are excluded from the median calculation since the Wilcoxon test ignores ties.
AUC0–24 = area under concentration (AUC) vs time curve (0 to 24 hours post-dose); CL/F = apparent oral clearance; Tmin = time to achieve minimum (trough) plasma concentration; Tmax = time to achieve maximum plasma concentration; T1/2 = elimination half-life; Vd/F = apparent volume of distribution; Cmin= minimum plasma concentration; Cmax = maximum plasma concentration; C0 = initial concentration at time zero; C12 = concentration at 12 hours post-dose; C24 = concentration at 24 hours post-dose.